

30 June 2011

TENDER RESULTS

The PHARMAC Board (or Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010.

As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp.

Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where no brand is listed.

Chemical name	Presentation; Pack size and type	Subsidy and price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date
Amlodipine	Tab 2.5 mg; 100 tablets, bottle	\$2.45	Apo-Amlodipine (Amlodipine)	1 January 2012	1 April 2012

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Amlodipine	Tab 5 mg; 100 tablets, bottle	\$7.33	\$2.65	Apo-Amlodipine (Amlodipine)	1 August 2011	1 November 2011
Amlodipine	Tab 10 mg; 100 tablets, bottle	\$11.79	\$4.15	Apo-Amlodipine (Amlodipine)	1 August 2011	1 November 2011
Dipyridamole	Tab long-acting 150 mg; 60 tablets, bottle	\$11.52	\$11.52	Pytazen SR (Douglas)	-	1 November 2011
Ibuprofen	Tab long-acting 800 mg; 30 tablets, blister	\$9.12	\$8.12	Brufen SR (Abbott)	1 August 2011	1 November 2011
Iron polymaltose	Inj 50 mg per ml, 2 ml; 5 ampoules	\$20.95	\$19.90	Ferrum H (Aspen)	1 August 2011	1 November 2011
Oxazepam*	Tab 10 mg; 100 tablets, bottle	\$1.98 (\$5.89)	\$5.89	Ox-Pam (Douglas)	1 August 2011	1 November 2011
Oxazepam*	Tab 15 mg; 100 tablets, bottle	\$2.45 (\$8.13)	\$8.13	Ox-Pam (Douglas)	1 August 2011	1 November 2011

* Oxazepam 10 mg and 15 mg tablets will be fully subsidised from 1 August 2011.

3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Ibuprofen	Tab 200 mg; 1,000 tablets, blister	\$16.00	\$12.75	Arrowcare (Arrow)	1 December 2011	1 February 2012	1 May 2012	Ethics Ibuprofen (Multichem) Brufen*

* The subsidy for ibuprofen 400 mg and 600 mg tablets (Brufen) will be reduced due to the reduction in price of the reference product (ibuprofen 200 mg tablets). The new subsidies will be \$0.77 per 30 tablets for the 400 mg tablets and \$1.15 per 30 tablets for the 600 mg tablets. The 400 mg and 600 mg tablets are not being delisted.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Amlodipine	Tab 2.5 mg; 100 tablets, bottle	\$2.45	Apo-Amlodipine (Amlodipine)	1%	1 January 2012	1 March 2012

5. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Amlodipine	Tab 5 mg; 100 tablets, bottle	\$7.33	\$2.65	Apo-Amlodipine (Amlodipine)	1%	1 August 2011	1 October 2011
Amlodipine	Tab 10 mg; 100 tablets, bottle	\$11.79	\$4.15	Apo-Amlodipine (Amlodipine)	1%	1 August 2011	1 October 2011

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Cefotaxime	Inj 500 mg; 1 vial	\$1.69	\$1.90	Cefotaxime Sandoz (Sandoz)	1%	1 August 2011	1 October 2011
Dipyridamole	Tab long-acting 150 mg; 60 tablets, bottle	\$11.52	\$11.52	Pytazen SR (Douglas)	1%	-	1 October 2011
Ibuprofen	Tab long-acting 800 mg; 30 tablets, blister	\$9.12	\$8.12	Brufen SR (Abbott)	1%	1 August 2011	1 October 2011
Iron polymaltose	Inj 50 mg per ml, 2 ml; 5 ampoules	\$20.95	\$19.90	Ferrum H (Aspen)	1%	1 August 2011	1 October 2011

6. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Cefotaxime	Inj 1 g; 10 vials	\$1.90 (per 1 injection)	\$15.58 (per 10 injections)	DBL Cefotaxime (Hospira)	1%	1 September 2011	1 November 2011	Cefotaxime Sandoz (Sandoz)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name	Line Item	Chemical Name	Line Item
Bupivacaine Hydrochloride with Adrenaline	Inj 0.25% with 1:400,000 of adrenaline, 10 ml	Ibuprofen	Tab 400 mg
Bupivacaine Hydrochloride with Adrenaline	Inj 0.25% with 1:400,000 of adrenaline, 10 ml theatre pack	Intra-Uterine Device	IUD
Bupivacaine Hydrochloride with Adrenaline	Inj 0.25% with 1:400,000 of adrenaline, 20 ml	Lignocaine (lidocaine)	Topical soln 4%
Bupivacaine Hydrochloride with Adrenaline	Inj 0.5% with 1:200,000 of adrenaline, 10 ml	Lithium Carbonate	Tab long-acting 400 mg
Bupivacaine Hydrochloride with Adrenaline	Inj 0.5% with 1:200,000 of adrenaline, 10 ml theatre pack	Octreotide (somatostatin analogue)	LAR inj 10 mg
Bupivacaine Hydrochloride with Adrenaline	Inj 0.5% with 1:200,000 of adrenaline, 20 ml	Octreotide (somatostatin analogue)	LAR inj 20 mg
Dacarbazine	Inj 100 mg	Octreotide (somatostatin analogue)	LAR inj 30 mg
Dacarbazine	Inj 1000 mg	Oxycodone Hydrochloride	1 mg per ml, 10 ml pre-filled syringe
Dacarbazine	Inj 500 mg	Oxycodone Hydrochloride	1 mg per ml, 50 ml prefilled syringe
Dacarbazine	Inj 600 mg	Oxycodone Hydrochloride	Cap 10 mg
Daunorubicin	Inj 20 mg	Oxycodone Hydrochloride	Cap 20 mg
Dobutamine	Inj 250 mg	Oxycodone Hydrochloride	Cap 5 mg
Emtricitabine	Cap 200 mg	Oxycodone Hydrochloride	Oral liq 5 mg per 5 ml
Ephedrine	Inj 3 mg per ml, 10 ml prefilled syringe	Oxycodone	Inj 10 mg per ml, 1 ml
Fusidic acid	Eye drops 1%	Oxycodone	Inj 10 mg per ml, 2 ml
Glipizide	Tab 5 mg	Oxycodone	Inj 50 mg per ml
Heparinised saline	Inj 100 iu per ml, 5 ml prefilled syringe	Pethidine Hydrochloride	Inj 50 mg per ml, 1.5 ml
Hypromellose	Eye drops 0.5% with or without dextran	Pravastatin	Tab 10 mg
Ibuprofen *	Tab 200 mg	Tenoxicam	Inj 20 mg

*Only the hospital tender for ibuprofen tab 200 mg has been declined.

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2009/10 Invitation to Tender, dated 4 December 2009:

Chemical Name	Line Item	Chemical Name	Line Item
Dexamethasone	Tab 0.5 mg	Phenobarbitone	Inj 200 mg per ml, 1 ml
Dexamethasone	Tab 1 mg	Tobramycin	Powder BP
Dexamethasone	Tab 4 mg	Topotecan	Inj 1 mg
Fluorouracil sodium	Inj 25 mg per ml, 100 ml	Topotecan	Inj 4 mg
Miconazole	Oral gel 20 mg per g		

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2008/09 Invitation to Tender, dated 23 December 2008:

Chemical Name	Line Item	Chemical Name	Line Item
Felodipine	Tab 2.5 mg		

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.